A Study of JNJ-1761981 in Participants With Solid Tumors

NCT07525141 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: JNJ-1761981
DRUG: Cetrelimab

Sponsor

Johnson & Johnson Enterprise Innovation Inc.